Diffuse large B-cell lymphoma: open trials in China

• NCT07035379

  A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

  Trial Treatment · Phase 1/2 · Zhejiang Teruisi Pharmaceutical Inc.

  Chinese Academy of Medical Sciences Cancer Hospital, Beijing

  Registry updated 2025-08-22

• NCT06664411

  Pola-ZR2P in Previously Untreated DLBCL

  Trial Treatment · Phase 2 · Navy General Hospital, Beijing

  Navy General Hospital, Beijing

  Registry updated 2025-08-19

• NCT07078500

  Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

  Trial Treatment · Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine

  Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

  Registry updated 2025-08-19

• NCT06827782

  Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

  Trial Treatment · Phase 1 · Second Affiliated Hospital, Zhejiang University, School of Medicine

  2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

  Registry updated 2025-08-15

• NCT07124936

  A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

  Trial Treatment · Phase 1/2 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

  Peking University Cancer Hospital, Beijing · The First Hospital of Jilin University, Changchun · HunanCancer Hospital, Changsha · West China Hospital，Sichuan University, Chengdu · Fujian Cancer Hospital, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou · Affiliated Tumor Hospital of Harbin Medical University, Harbin · Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital), Jinan · The Second Affiliated Hospital of Kunming Medical UniversityThe Second Affiliated Hospital of Kunming Medical University, Kunming · Yunnan Cancer Hospital, Kunming · The First Affiliated Hospital of NanChang University, Nanchang · The Affiliated Tumor Hospital of Guangxi Medical University, Nanning · Shengjing Hospital affiliated to China Medical University, Shenyang · Second Affiliated Hospital of Soochow University, Suzhou · Shanxi Cancer hospital, Taiyuan · Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an · The First Affiliated Hospital of Zhengzhou University, Zhengzhou · Henan Cancer Hospital, Zhengzhou

  Registry updated 2025-08-15

• NCT07122609

  Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  Trial Treatment · Phase 2 · Ruijin Hospital

  Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

  Registry updated 2025-08-14

• NCT06375733

  A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

  Trial Treatment · Phase 1/2 · Genfleet Therapeutics (Shanghai) Inc.

  Guangxi Medical University Cancer hospital & Guangxi Cancer Institute, Nanning · Affiliated Cancer Hospital of Zhengzhou University(Henan Cancer Hospital), Zhengzhou

  Registry updated 2025-08-12

• NCT06213636

  Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

  Trial Treatment · Phase 1/2 · Essen Biotech

  District One Hospital, Beijing

  Registry updated 2025-08-06

• NCT06651853

  Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

  Trial Treatment · Phase 2 · The First Affiliated Hospital of Xiamen University

  The First Affiliated hospital of Xiamen University, Xiamen

  Registry updated 2025-07-23

• NCT07072208

  Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL

  Trial Treatment · The First Affiliated Hospital of Soochow University

  The First Affiliated Hospital of Soochow University, Suzhou

  Registry updated 2025-07-18

• NCT07070648

  Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

  Research · Fudan University

  Fudan University Shanghai Cancer Center, Shanghai

  Registry updated 2025-07-17

• NCT06682130

  Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL

  Trial Treatment · Phase 2 · The First Affiliated Hospital of Soochow University

  The First Affiliated Hospital of Soochow University, Suzhou

  Registry updated 2025-07-14

• NCT07034508

  A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

  Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China

  China Institute of Hematology and Blood Diseases Hospital, Tianjin

  Registry updated 2025-06-24

• NCT07001540

  Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

  Trial Treatment · Phase 2 · Fudan University

  Fudan University Shanghai Cancer Center, Shanghai

  Registry updated 2025-06-19

• NCT06742502

  Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL

  Trial Treatment · Phase 2 · Sun Yat-sen University

  Fujian Cancer Hospital, Fuzhou · Sun yat-sen university cancer cencer, Guangzhou

  Registry updated 2025-06-05

• NCT06244368

  GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

  Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China

  Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin

  Registry updated 2025-05-14

• NCT03936153

  Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  Trial Treatment · Phase 2 · Xynomic Pharmaceuticals, Inc.

  Cancer Hospital, Chinese Academy of Medical Sciences, Beijing · China-Japan Friendship Hospital, Beijing · Peking University Third Hospital, Beijing · West China Hospital，Sichuan University, Chengdu · The First Affiliate Hospital of Dalian Medical University, Dalian · Fujian Provincial Cancer Hospital, Fuzhou · Fujian Medical University Union Hospital, Fuzhou · Sun Yai-Sen Memorial Hospital Sun Yai-Sen University, Guangzhou · Cancer Center of Guangzhou Medical University, Guangzhou · Zhejiang Cancer Hospital, Hangzhou · The Affiliated Tumor Hospital of Harbin Medical University, Harbin · The First Hospital of Lanzhou University, Lanzhou · LinYi Cancer Hospital, Linyi · Nantong Tumor Hospital, Nantong · Shanghai Jiao Tong University School Medicine, Shanghai · Fudan University Shanghai Cancer Center, Shanghai · Second People's Hospital of Shenzhen, Shenzhen · The Forth Hospital of Hebei Medical University, Shijiazhuang · First Hospital of Shanxi Medical University, Taiyuan · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · The affiliated hospital of xuzhou medical university, Xuzhou · Henan Cancer Hospital, Zhengzhou · The First Affiliated Hospital of Zhengzhou University, Zhengzhou

  Registry updated 2025-04-10

• NCT06760039

  Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

  Trial Treatment · Phase 1/2 · Sun Yat-sen University

  Beijing Tongren Hospital, Beijing · Fujian Provincial Cancer Hospital, Fuzhou · Ganzhou Cancer Hospital, Ganzhou · The Affiliated Hospital of Guangdong Medical University, Guangzhou · The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou · Guangxi Zhuang Autonomous Region Cancer Hospital, Guilin · Gansu Provincial Cancer Hospital, Lanzhou · Jiangxi Provincial Cancer Hospital, Nanchang · Shenzhen People's Hospital, Shenzhen · The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai

  Registry updated 2025-04-03

• NCT06902012

  Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma

  Trial Treatment · Phase 1/2 · Zhujiang Hospital

  Zhujiang Hospital, Guangzhou

  Registry updated 2025-03-30

• NCT06854445

  Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

  Trial Treatment · Phase 2 · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

  The Second Xiangya Hospital of Central South University, Changsha · Hunan Cancer Hospital, Changsha · Sichuan Provincal People's Hospital, Chengdu · The Second Affiliated Hospital of Dalian Medical University, Dalian · Affiliated Cancer Hospital and insititute Guangzhou Medical University, Guangzhou · The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou · Harbin Medical University Cancer Hospital, Harbin · Shandong Cancer Hospital, Jinan · Gansu Provincial Cancer Hospital, Lanzhou · The Affiliated Hospital of Southwest Medical University, Luzhou · Jiangxi Cancer Hospital, Nanchang · Nanjing Drum Tower hospital, Nanjing · Guangxi Medical University Cancer Hospital, Nanning · The Fourth Hospital of Hebei Medical University, Shijiazhuang · The First Affiliated Hospital of Soochow University, Suzhou · Shanxi Provincial Cancer Hospital, Taiyuan · Weihai Central Hospital, Weihai · Zhongnan Hospital of Wuhan University, Wuhan · Hubei Cancer Hospital (HBCH), Wuhan · The First Affiliated Hospital of Wannan Medical College, Wuhu · The First Affiliated hospital of Xiamen University, Xiamen · The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an · Henan Cancer Hospital, Zhengzhou · The First Affiliated Hospital of Zhengzhou University, Zhengzhou

  Registry updated 2025-03-24

• NCT06890585

  Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL

  Trial Treatment · Phase 2 · Li Zhiming

  Sun Yat-sen University Cancer Center, Guangzhou

  Registry updated 2025-03-24

• NCT06891157

  Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes

  Trial Treatment · Phase 2 · The First Affiliated Hospital with Nanjing Medical University

  The First Affiliated Hospital with Nanjing Medical University, Nanjing

  Registry updated 2025-03-24

• NCT06764017

  CHiR Therapy for Elderly DLBCL Intolerant to Chemo

  Trial Treatment · Phase 2 · First Affiliated Hospital of Ningbo University

  The First Affiliated Hospital of Ningbo University, Ningbo

  Registry updated 2025-03-19

• NCT06758037

  Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy

  Trial Treatment · Phase 2 · First Affiliated Hospital of Ningbo University

  The First Affiliated Hospital of Ningbo University, Ningbo

  Registry updated 2025-03-18

• NCT05487170

  A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

  Trial Treatment · Phase 1/2 · Ranok Therapeutics (Hangzhou) Co., Ltd.

  Beijing Cancer Hospital, Beijing · Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

  Registry updated 2025-03-04

All Diffuse large B-cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error